Stay updated on EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial
Sign up to get notified when there's something new on the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page.

Latest updates to the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedAdded EU registry identifier 2024-512050-13-00 to the study record and updated dates; removed the older EudraCT number and a government-funding notice.SummaryDifference0.6%

- Check42 days agoChange DetectedNo significant additions or deletions were detected on the page; the study details, eligibility criteria, and locations remain the same.SummaryDifference0.4%

- Check49 days agoChange DetectedThe Locations section now lists 11 sites, adding L'Hospitalet de Llobregat, Barcelona, Spain, and removing Lyon, France. The total number of locations changed from 12 to 11, and the L'Hospitalet de Llobregat entry was reformatted from Catalonia to Barcelona.SummaryDifference0.5%

- Check71 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check78 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

Stay in the know with updates to EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page.